131 related articles for article (PubMed ID: 32450073)
1. Map3k1 Loss Cooperates with Braf
Trucco LD; Mundra PA; García-Martínez P; Hogan K; Baenke F; Dhomen N; Pavet V; Marais R
J Invest Dermatol; 2021 Jan; 141(1):221-225.e6. PubMed ID: 32450073
[No Abstract] [Full Text] [Related]
2. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
[TBL] [Abstract][Full Text] [Related]
3. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.
Pearlstein MV; Zedek DC; Ollila DW; Treece A; Gulley ML; Groben PA; Thomas NE
J Cutan Pathol; 2014 Sep; 41(9):724-32. PubMed ID: 24917033
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous BRAF
Wuethrich A; Dey S; Koo KM; Sina AAI; Trau M
Methods Mol Biol; 2021; 2265():265-276. PubMed ID: 33704721
[TBL] [Abstract][Full Text] [Related]
5. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
[No Abstract] [Full Text] [Related]
6. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
[TBL] [Abstract][Full Text] [Related]
7. Identification of BRAF 3'UTR Isoforms in Melanoma.
Marranci A; Tuccoli A; Vitiello M; Mercoledi E; Sarti S; Lubrano S; Evangelista M; Fogli A; Valdes C; Russo F; Monte MD; Caligo MA; Pellegrini M; Capobianco E; Tsinoremas N; Poliseno L
J Invest Dermatol; 2015 Jun; 135(6):1694-1697. PubMed ID: 25685929
[No Abstract] [Full Text] [Related]
8. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
10. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?
Lade-Keller J; Kristensen LS; Riber-Hansen R; Guldberg P; Hansen LL; Steiniche T; Hager H
J Clin Pathol; 2013 Aug; 66(8):723-5. PubMed ID: 23526598
[No Abstract] [Full Text] [Related]
11. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
12. Chemokines in the melanoma metastasis biomarkers portrait.
Neagu M; Constantin C; Longo C
J Immunoassay Immunochem; 2015; 36(6):559-66. PubMed ID: 25839711
[TBL] [Abstract][Full Text] [Related]
13. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
14. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.
Venesio T; Chiorino G; Balsamo A; Zaccagna A; Petti C; Scatolini M; Pisacane A; Sarotto I; Picciotto F; Risio M
Mod Pathol; 2008 Jun; 21(6):716-26. PubMed ID: 18408659
[TBL] [Abstract][Full Text] [Related]
15. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
16. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
18. Ocular Metastasis of BRAF+ Cutaneous Malignant Melanoma.
Gonzalez A; Miles JF; Khurshid GS
Ophthalmol Retina; 2018 Jan; 2(1):71. PubMed ID: 31047306
[No Abstract] [Full Text] [Related]
19. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
20. Systemic Therapy Options for Patients With Unresectable Melanoma.
Yushak M; Chapman P; Robert C; Kudchadkar R
Am Soc Clin Oncol Educ Book; 2017; 37():661-672. PubMed ID: 28561662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
